Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DYRK1A

Gene summary for DYRK1A

Gene summary.

Gene information	Species	Human
	Gene symbol	DYRK1A
	Gene ID	1859
	Gene name	dual specificity tyrosine phosphorylation regulated kinase 1A
	Gene Alias	DYRK
	Cytomap	21q22.13
	Gene Type	protein-coding
	GO ID	GO:0000226
	UniProtAcc	Q13627

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1859	DYRK1A	CCI_1	Human	Cervix	CC	4.56e-17	1.32e+00	0.528
1859	DYRK1A	CCI_2	Human	Cervix	CC	1.51e-13	1.86e+00	0.5249
1859	DYRK1A	CCI_3	Human	Cervix	CC	6.46e-19	1.30e+00	0.516
1859	DYRK1A	HTA11_3410_2000001011	Human	Colorectum	AD	7.50e-34	-8.55e-01	0.0155
1859	DYRK1A	HTA11_2487_2000001011	Human	Colorectum	SER	1.35e-06	-5.81e-01	-0.1808
1859	DYRK1A	HTA11_2951_2000001011	Human	Colorectum	AD	9.28e-05	-8.21e-01	0.0216
1859	DYRK1A	HTA11_78_2000001011	Human	Colorectum	AD	3.64e-02	-4.23e-01	-0.1088
1859	DYRK1A	HTA11_3361_2000001011	Human	Colorectum	AD	4.82e-13	-7.02e-01	-0.1207
1859	DYRK1A	HTA11_696_2000001011	Human	Colorectum	AD	1.14e-16	-5.71e-01	-0.1464
1859	DYRK1A	HTA11_866_2000001011	Human	Colorectum	AD	8.04e-15	-5.70e-01	-0.1001
1859	DYRK1A	HTA11_5212_2000001011	Human	Colorectum	AD	8.02e-06	-6.60e-01	-0.2061
1859	DYRK1A	HTA11_5216_2000001011	Human	Colorectum	SER	6.25e-06	-5.86e-01	-0.1462
1859	DYRK1A	HTA11_546_2000001011	Human	Colorectum	AD	5.32e-05	-6.20e-01	-0.0842
1859	DYRK1A	HTA11_9341_2000001011	Human	Colorectum	SER	2.85e-02	-7.33e-01	-0.00410000000000005
1859	DYRK1A	HTA11_7862_2000001011	Human	Colorectum	AD	4.64e-10	-8.13e-01	-0.0179
1859	DYRK1A	HTA11_866_3004761011	Human	Colorectum	AD	2.44e-18	-7.20e-01	0.096
1859	DYRK1A	HTA11_4255_2000001011	Human	Colorectum	SER	9.20e-03	-6.60e-01	0.0446
1859	DYRK1A	HTA11_9408_2000001011	Human	Colorectum	AD	1.17e-02	-8.66e-01	0.0451
1859	DYRK1A	HTA11_8622_2000001021	Human	Colorectum	SER	3.31e-06	-6.98e-01	0.0528
1859	DYRK1A	HTA11_10623_2000001011	Human	Colorectum	AD	1.14e-05	-5.38e-01	-0.0177

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:190290310	Cervix	CC	regulation of supramolecular fiber organization	92/2311	383/18723	1.49e-10	2.48e-08	92
GO:004325410	Cervix	CC	regulation of protein-containing complex assembly	96/2311	428/18723	2.91e-09	3.05e-07	96
GO:005125810	Cervix	CC	protein polymerization	70/2311	297/18723	5.20e-08	3.11e-06	70
GO:004348410	Cervix	CC	regulation of RNA splicing	42/2311	148/18723	1.25e-07	6.24e-06	42
GO:003227110	Cervix	CC	regulation of protein polymerization	57/2311	233/18723	2.37e-07	1.03e-05	57
GO:19033119	Cervix	CC	regulation of mRNA metabolic process	64/2311	288/18723	1.71e-06	5.64e-05	64
GO:003311910	Cervix	CC	negative regulation of RNA splicing	13/2311	25/18723	1.83e-06	5.89e-05	13
GO:00485118	Cervix	CC	rhythmic process	65/2311	298/18723	2.79e-06	8.04e-05	65
GO:19029048	Cervix	CC	negative regulation of supramolecular fiber organization	40/2311	167/18723	2.39e-05	4.17e-04	40
GO:004802410	Cervix	CC	regulation of mRNA splicing, via spliceosome	28/2311	101/18723	2.41e-05	4.19e-04	28
GO:00313339	Cervix	CC	negative regulation of protein-containing complex assembly	35/2311	141/18723	3.41e-05	5.55e-04	35
GO:00181057	Cervix	CC	peptidyl-serine phosphorylation	63/2311	315/18723	6.65e-05	9.47e-04	63
GO:00076238	Cervix	CC	circadian rhythm	46/2311	210/18723	6.76e-05	9.60e-04	46
GO:007233110	Cervix	CC	signal transduction by p53 class mediator	38/2311	163/18723	7.06e-05	9.85e-04	38
GO:00106399	Cervix	CC	negative regulation of organelle organization	68/2311	348/18723	7.40e-05	1.03e-03	68
GO:00182096	Cervix	CC	peptidyl-serine modification	66/2311	338/18723	9.58e-05	1.25e-03	66
GO:00506849	Cervix	CC	regulation of mRNA processing	33/2311	137/18723	1.06e-04	1.35e-03	33
GO:00514948	Cervix	CC	negative regulation of cytoskeleton organization	37/2311	163/18723	1.57e-04	1.88e-03	37
GO:20010209	Cervix	CC	regulation of response to DNA damage stimulus	46/2311	219/18723	1.92e-04	2.23e-03	46
GO:190331210	Cervix	CC	negative regulation of mRNA metabolic process	24/2311	92/18723	2.49e-04	2.77e-03	24

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DYRK1A

SNV

Missense_Mutation

c.217G>C

p.Asp73His

p.D73H

Q13627

protein_coding

deleterious(0)

benign(0.364)

TCGA-A2-A0EQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

DYRK1A

SNV

Missense_Mutation

c.1744C>G

p.His582Asp

p.H582D

Q13627

protein_coding

tolerated_low_confidence(0.18)

possibly_damaging(0.84)

TCGA-A2-A0EQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

DYRK1A

SNV

Missense_Mutation

c.1976N>T

p.Ser659Phe

p.S659F

Q13627

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.962)

TCGA-A8-A094-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DYRK1A

SNV

Missense_Mutation

c.1626C>A

p.Phe542Leu

p.F542L

Q13627

protein_coding

tolerated(0.05)

benign(0.001)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DYRK1A

SNV

Missense_Mutation

c.161N>T

p.Ser54Phe

p.S54F

Q13627

protein_coding

deleterious_low_confidence(0.01)

benign(0.044)

TCGA-AO-A0JC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

DYRK1A

SNV

Missense_Mutation

c.46C>T

p.Arg16Trp

p.R16W

Q13627

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.454)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

DYRK1A

SNV

Missense_Mutation

c.492G>C

p.Leu164Phe

p.L164F

Q13627

protein_coding

deleterious(0.02)

probably_damaging(0.949)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

DYRK1A

SNV

Missense_Mutation

c.2230N>C

p.Asp744His

p.D744H

Q13627

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.99)

TCGA-BH-A18P-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DYRK1A

SNV

Missense_Mutation

c.183G>C

p.Gln61His

p.Q61H

Q13627

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.626)

TCGA-D8-A1JP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

DYRK1A

SNV

Missense_Mutation

c.1898A>G

p.Tyr633Cys

p.Y633C

Q13627

protein_coding

deleterious_low_confidence(0.02)

probably_damaging(0.984)

TCGA-E2-A15E-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme1WO2011135259
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme15-1
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme23MPPDerivatives
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE	inhibitor	249565842
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme13INDY
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE	inhibitor	405560505
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme4Upper
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme12-3
1859	DYRK1A	DRUGGABLE GENOME, KINASE, ENZYME, TYROSINE KINASE, SERINE THREONINE KINASE		PMID28766366-Compound-Scheme18

Page: 1 2 3 4 5 6 7 8